Clear Review of the Scrambler Therapy

 

HEALTHTECH REPORTER ESSENTIALS:

Clear Review of the Scrambler Therapy

Dr. Jason Cooney describes Scrambler Therapy as a non-invasive neuromodulation technology designed to treat chronic neuropathic pain by interrupting and retraining abnormal pain signaling pathways in the nervous system. Rather than masking pain with medications or targeting inflammation directly, the therapy delivers controlled electrical signals through the skin to replace pain messages with non-pain information, effectively “rebooting” how the brain perceives pain.

What distinguishes Scrambler Therapy from conventional electrical stimulation devices is the proprietary algorithm behind its signal delivery. The system generates a constantly vacillating and dynamically changing electrical waveform, rather than a fixed or repetitive frequency. Traditional stimulation devices allow clinicians to adjust frequency or intensity, but once set, those signals remain constant. In contrast, Scrambler Therapy continuously varies its signal pattern. According to Dr. Cooney, this prevents the brain from adapting or compensating for the stimulus. Because the signal is always changing, the nervous system remains responsive and “listens” to the incoming information rather than habituating to it. This adaptive signaling is central to the therapy’s ability to disrupt entrenched pain patterns.

From a neurophysiological standpoint, Scrambler Therapy primarily targets C fibers, the unmyelinated sensory nerve fibers that transmit chronic pain signals from the skin to the central nervous system. The therapy delivers non-pain electrical information to these fibers, which then travel along the spinothalamic tract to the cerebral cortex. By repeatedly replacing pain messages with non-pain signals, the brain is gradually retrained to reinterpret sensory input from the affected region. Over time, this process can reduce or eliminate the perception of chronic pain. Dr. Cooney characterizes this process as a form of neural “rebooting,” in which maladaptive pain signaling is overwritten by new, non-painful input.

Clinically, Scrambler Therapy has been most extensively studied and applied in patients with Complex Regional Pain Syndrome (CRPS) and chemotherapy-induced peripheral neuropathy (CIPN). Dr. Cooney notes that the majority of patients treated in clinical practice fall into these two categories, with CRPS representing the primary indication and CIPN comprising a significant secondary group. In patients with chemotherapy-induced neuropathy, Scrambler Therapy often produces meaningful reductions in pain. However, Dr. Cooney observes that numbness and tingling may be less responsive in some individuals, particularly when nerve damage or demyelination is severe or irreversible. While pain can be significantly improved, sensory deficits may persist in certain cases due to underlying structural nerve injury.

Dr. Cooney emphasizes that Scrambler Therapy is most effective for neuropathic pain that is not caused by ongoing mechanical compression or structural pathology. For example, patients with degenerative spinal conditions involving active nerve compression may experience temporary pain relief during treatment, but symptoms are likely to return if the underlying mechanical cause is not addressed. In contrast, neuropathic pain resulting from stroke, infection, surgery, chemotherapy, or chronic neurological injury may respond more favorably when the original insult is no longer actively damaging the nerve tissue. In these cases, Scrambler Therapy can help interrupt persistent pain signaling that remains long after the initial injury has healed.

One of the defining advantages of Scrambler Therapy, according to Dr. Cooney, is its non-invasive nature and favorable safety profile. The treatment does not involve injections, surgery, implanted devices, or pharmaceuticals. He highlights that the therapy is well tolerated and associated with minimal risk, making it suitable even for pediatric populations. In his clinical experience, children and adolescents with CRPS—who represent a notable portion of CRPS cases—have shown dramatic functional improvements following treatment. Dr. Cooney recounts cases in which young patients arrived dependent on crutches and unable to attend school, only to regain mobility and return to daily activities within weeks. He underscores that the absence of medication-related side effects is particularly important in younger patients, where long-term pharmaceutical management carries significant risks.

Dr. Cooney also places Scrambler Therapy within a growing body of clinical research and international adoption. The technology has been in clinical use for more than a decade and is now available in multiple countries, including the United States, Germany, and Italy. While early adoption relied heavily on anecdotal clinical success, Dr. Cooney notes that the therapy is increasingly supported by formal studies conducted at major academic and clinical institutions. This expanding research base has helped move Scrambler Therapy beyond experimental or fringe status toward broader clinical legitimacy within pain medicine.

Despite its demonstrated benefits, Dr. Cooney is careful to acknowledge current limitations in objective outcome measurement. Clinical improvements are typically assessed using patient-reported pain scales, which, while meaningful to patients, remain subjective measures. He recognizes the need for more objective validation methods and welcomes efforts to pair clinical outcomes with measurable physiological or imaging-based biomarkers. Establishing quantifiable evidence of neurological or tissue-level change, he notes, would further strengthen the medical community’s confidence in neuromodulation-based pain therapies such as Scrambler.

In summary, Dr. Cooney presents Scrambler Therapy as a clinically validated, non-invasive neuromodulation approach that addresses chronic neuropathic pain by retraining how the brain processes sensory information. Through dynamically changing electrical signals delivered to peripheral nerve fibers, the therapy disrupts maladaptive pain messaging and replaces it with non-pain input, enabling meaningful functional recovery in conditions such as CRPS and chemotherapy-induced neuropathy.

 

SEE PART 1 OF THIS STORY

Scrambler Therapy and the Clinical Work of Dr. Jason Cooney

Reframing Chronic Neuropathic Pain Through Non-Invasive Neuromodulation

 

By: Lennard M. Goetze, Ed.D

 

Chronic neuropathic pain remains one of the most difficult clinical challenges in modern medicine. Patients with conditions such as Complex Regional Pain Syndrome (CRPS), chemotherapy-induced peripheral neuropathy (CIPN), and idiopathic neuropathy often cycle through medications, injections, and procedures with limited or short-lived benefit. Within this therapeutic gap, Scrambler Therapy (also known as Calmare® Therapy) has emerged as a non-invasive neuromodulation approach designed to interrupt maladaptive pain signaling and restore functional quality of life.

 

At the forefront of this clinical application in the New York–New Jersey region is Dr. Jason Cooney, DC, Clinical Director at Scrambler Therapy NJ. With more than two decades of experience in chiropractic rehabilitation and physiotherapy, Dr. Cooney has focused his practice on patients whose pain has persisted despite conventional care. Trained by his father, Dr. Michael Cooney, DC—an early adopter and national educator in Calmare Therapy—Dr. Cooney represents a second generation of clinicians committed to advancing non-pharmacologic, evidence-informed pain management.

How Scrambler Therapy Works

Scrambler Therapy is an FDA-cleared medical device designed to treat neuropathic pain by altering how the nervous system encodes pain information. Unlike conventional electrical stimulation used in physical therapy (e.g., TENS), the Scrambler system uses multiple proprietary signal patterns that change continuously during treatment sessions. These variable waveforms are intended to prevent neural adaptation and maintain effective communication with sensory nerve fibers.

 

Electrode pads are placed strategically along dermatomal distributions above and below the region of pain rather than directly on the most painful site. The device transmits non-painful signals primarily through small sensory fibers that project to the spinal cord and onward to higher pain-processing centers. Over repeated sessions, these signals aim to replace persistent “danger” messages with neutral or corrective input, reducing the brain’s tendency to perpetuate a chronic pain loop.

Clinically, the approach is grounded in the understanding that chronic pain is not solely a peripheral tissue problem; it is also a learned neural pattern that can become reinforced over time. By providing consistent, non-threatening sensory input, Scrambler Therapy seeks to recalibrate pain pathways that remain locked in a heightened state of reactivity.

 

Clinical Indications and Limitations

Dr. Cooney reports the strongest outcomes in patients with neuropathic pain syndromes, particularly CRPS and CIPN. These conditions often involve abnormal neuroinflammatory responses and maladaptive sensory processing following injury, surgery, or chemotherapy exposure. In these populations, Scrambler Therapy has demonstrated meaningful reductions in pain intensity for a substantial proportion of patients, often enabling improvements in sleep, mobility, and daily function.

 

However, the therapy is not positioned as a universal solution for all pain. Structural conditions such as severe spinal stenosis, advanced degenerative disease, or mass-occupying lesions fall outside its therapeutic scope. Because Scrambler Therapy does not correct biomechanical compression or tissue destruction, patient selection and diagnostic clarity are essential. Dr. Cooney emphasizes that the therapy is best viewed as a neurofunctional intervention—one that targets dysfunctional signaling rather than structural pathology.

 

Treatment Protocol and Patient Experience

A standard course of Scrambler Therapy typically involves daily sessions over a two-week period, with each visit lasting approximately one hour. Patients do not experience painful stimulation during treatment; instead, they describe mild tingling or tapping sensations. Early sessions may provide only temporary relief lasting hours, but cumulative exposure often extends the duration of symptom reduction. In some cases, patients experience prolonged remission, while others benefit from periodic “booster” sessions to maintain gains.

 

For individuals whose pain has limited activity, the reduction in discomfort can create an opening for functional rehabilitation. Dr. Cooney integrates Scrambler Therapy within a broader care model that includes chiropractic methods, physiotherapy, and movement-based recovery strategies. As pain diminishes, patients are more capable of re-engaging in mobility work and strength conditioning, indirectly supporting muscular recovery that had been hindered by chronic pain.

 

Research Context and Institutional Adoption

While early skepticism often accompanies novel neuromodulation technologies, Scrambler Therapy has gradually gained traction within academic and hospital settings. Clinical evaluations conducted by major medical centers have contributed to growing acceptance of the modality for neuropathic pain syndromes. The device itself was developed in Italy and refined through international clinical collaboration, with training programs disseminated across Europe and the United States.

 

Institutional interest is also expanding within veteran health systems, where neuropathy related to toxic exposures and injury presents a persistent care challenge. This broader uptake reflects a shift toward integrative pain models that prioritize non-opioid, non-surgical interventions when appropriate.

 

A Patient-Centered Clinical Ethos

Dr. Cooney’s clinical identity centers on compassionate, personalized care for patients who have exhausted conventional options. His practice frequently receives referrals from major medical centers, underscoring the role of Scrambler Therapy as a complementary option within multidisciplinary pain management. Beyond individual care, he advocates for responsible education among clinicians, emphasizing that device-based therapies must be applied with neurological understanding and careful patient screening.

 

In an era marked by opioid fatigue and growing awareness of neuroplastic pain mechanisms, Scrambler Therapy represents a targeted attempt to “reset” maladaptive signaling rather than merely suppress symptoms. While not curative for every patient, the approach reflects a broader clinical movement: reframing chronic pain as a modifiable neurobiological process and expanding the toolkit of non-invasive interventions available to clinicians and patients alike.

 

  

PART 2 —

FROM “PAIN” TO THE MEASURABLE:

Why Non-Invasive Energy Therapies Are Reshaping Modern Care

By Dr. Robert Bard, MD, DABR, FAIUM, FASLMS

When I read Dr. Jason Cooney’s account of Scrambler Therapy, what stood out wasn’t only the “wow” stories—though those matter—it was the clinical logic behind why this category of care is expanding. Scrambler Therapy (Calmare®) is part of a broader movement toward non-invasive, energy-based and neuromodulation therapies that aim to reduce symptoms while avoiding the risk, recovery, and downstream complications associated with procedures and long-term drug dependence. In 2026, this isn’t a fringe trend; it’s a practical response to a persistent problem: chronic neuropathic suffering that too often outlives the standard toolbox.

Here’s the pivotal reframing I advocate: we should talk less about pain as a vague sensation and more about inflammation, neural signaling dysfunction, and maladaptive neuroplasticity—because those are closer to what we can evaluate, monitor, and validate. “Pain” is real, but it is also subjective. Inflammation and neurologic dysregulation are the measurable terrain underneath many pain syndromes, especially neuropathic conditions.

Scrambler Therapy exemplifies this shift. The mechanism isn’t about “blocking” discomfort—it’s about modulating the information stream carried by sensory fibers and processed centrally. A phase II randomized trial comparing Scrambler Therapy to TENS in chemotherapy-induced peripheral neuropathy (CIPN) reported better outcomes for Scrambler in that setting, supporting the concept that not all “electrostim” is created equal. Earlier clinical research also suggested Scrambler could outperform guideline-based drug management for certain chronic neuropathic pain states. Reviews describe Scrambler as a non-invasive method intended to reorganize maladaptive pain signaling pathways—exactly the direction modern neuro-therapeutics is heading.

To review, the vast market of non-invasive energy therapies includes:

·        Scrambler Therapy (Calmare®):
A specialized neuromodulation system that delivers continuously varied signal patterns designed to disrupt chronic pain encoding. Unlike fixed waveform TENS, Scrambler’s algorithmic variability aims to prevent nerve adaptation and promote longer-lasting reductions in pain intensity, particularly in neuropathic syndromes such as CRPS and chemotherapy-induced peripheral neuropathy.

· Pulsed Electromagnetic Field (PEMF) Therapy:
PEMF applies pulsating magnetic fields to tissues to influence cellular behavior. Research suggests potential benefits in pain reduction, improved blood flow, and reduced inflammation for conditions ranging from osteoarthritis to soft-tissue injury. Because it affects tissues at the cellular level, PEMF is frequently integrated into rehabilitation and chronic pain clinics.

·        Shockwave Therapy:
Shockwave uses focused high-amplitude acoustic waves to deliver mechanical energy deep into musculoskeletal tissues. Originally developed for urology, therapeutic shockwave promotes neovascularization, cellular regeneration, collagen remodeling, and reduction of chronic inflammation in tendon, ligament, and muscle structures. Clinically, it has shown efficacy for plantar fasciitis, Achilles tendinopathy, and chronic myofascial pain syndromes. Shockwave is non-invasive, typically requires only a few outpatient sessions, and often leads to measurable functional gains.

·       Photobiomodulation (Low-Level Laser / Red Light Therapy): Light at specific wavelengths can penetrate into tissues, triggering biochemical cascades that reduce oxidative stress and inflammatory mediators. Studies have reported reductions in joint pain, improved tissue healing rates, and improved outcomes in soft-tissue injury.

·        High-Intensity Focused Electromagnetic (HIFEM) and Radiofrequency Devices:
These platforms use electrical or thermal energy to stimulate deep tissues, sometimes with neuromuscular engagement. While originally developed for aesthetic or muscle-toning purposes, some applications show promise in rehabilitative and pain-related contexts due to improved circulation and neuromuscular normalization.

·        Ultrasound-Guided Neuromodulation:
A growing frontier, using focused ultrasound waves to target deep nervous structures and modulate pain pathways with precision. Clinical trials are underway exploring applications in chronic back pain, peripheral neuropathy, and even central neuromodulation.

·        TENS (Transcutaneous Electrical Nerve Stimulation): Large evidence syntheses report moderate-certainty evidence that pain intensity is lower during or immediately after TENS compared with placebo, with a strong safety profile. In neuropathic pain specifically, recent meta-analytic work suggests TENS may reduce pain to a modest degree, with evidence quality varying by condition and study design.

Why is the trend accelerating? Because many pharmacologic options for neuropathic pain deliver only modest efficacy across heterogeneous patient populations, leaving clinicians and patients searching for better pathways. Non-invasive energy therapies offer a rational alternative: reduce symptom load, calm the nervous system, and restore function—often without adding systemic side effects.

My position is simple: non-invasive matters because it lowers barriers to care, reduces cumulative risk, and invites objective monitoring. The future belongs to therapies that are not only effective, but verifiable. That means pairing these interventions with measurable endpoints—functional testing, neurovascular assessment, imaging-guided monitoring, and physiologic biomarkers—so we can show what is changing, not just hear that it “feels better.”

That’s the real promise here: a new standard where chronic “pain” is approached as a treatable, trackable neuro-inflammatory condition—and where the best technologies win because they can demonstrate outcomes, not because they make the loudest claims.

 

References:

American Academy of Neurology. (2019). A comprehensive algorithm for the management of neuropathic pain: Best practice recommendations. Pain Medicine. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544553/ — This guideline article reviews evidence-based approaches for neuropathic pain and contextualizes treatment strategies spanning pharmacologic and neuromodulation therapies.

Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., … Wallace, M. S. (2003). Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Archives of Neurology, 60(11), 1524–1534. https://doi.org/10.1001/archneur.60.11.1524 — A foundational overview of neuropathic pain mechanisms and clinical management strategies, widely referenced in clinical pain literature.

Mayo Clinic. (n.d.). Peripheral neuropathy: Diagnosis and treatment. Retrieved from https://www.mayoclinic.org/diseases-conditions/peripheral-neuropathy/diagnosis-treatment/drc-20352067 — Mayo Clinic describes Scrambler Therapy as an option that uses electrical impulses to send non-painful signals to the brain, aiming to retrain pain perception.

Mayo Clinic. (n.d.). Scrambler Therapy in treating pain and peripheral neuropathy in patients previously treated with chemotherapy [Clinical trial summary]. Retrieved from https://www.mayo.edu/research/clinical-trials/cls-20116107 — Details a clinical trial evaluating Scrambler Therapy for chemotherapy-induced peripheral neuropathy.

Mayo Clinic. (n.d.). A study comparing Scrambler Therapy versus TENS therapy in treating patients with chemotherapy-induced peripheral neuropathy. Retrieved from https://www.mayo.edu/research/clinical-trials/cls-20199631 — This randomized clinical trial compares Scrambler Therapy with conventional TENS therapy for neuropathy symptoms.

Marineo, G. (2016). Scrambler Therapy for the management of chronic pain. Pain Management, 6(2), 12–20. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973603/ — A review of Scrambler Therapy mechanisms and early clinical evidence supporting its use in chronic pain syndromes.

National Cancer Institute. (n.d.). Chemotherapy-induced peripheral neuropathy. Retrieved from https://en.wikipedia.org/wiki/Chemotherapy-induced_peripheral_neuropathy — Overview of CIPN’s clinical impact and prevalence among patients receiving chemotherapeutic agents.

 

Copyright Notice

© 2026 AngioInstitute – Institute for Global Health Innovations. All rights reserved. This work and all materials contained herein are the intellectual property of AngioInstitute (Institute for Global Health Innovations) and its authorized contributors. No part of this manuscript may be reproduced, stored in a retrieval system, transmitted, distributed, or shared in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior written permission from the publisher. All content is protected under applicable United States and international copyright, trademark, and intellectual property laws. Any trademarks, service marks, product names, or company names referenced herein are the property of their respective owners and are used for identification purposes only. This publication is provided for educational and informational purposes only and does not constitute medical, legal, or professional advice. Clinical decisions should be made in consultation with qualified healthcare professionals. The AngioInstitute does not assume liability for the application or misuse of any information contained herein.

Why Visionbody™ is changing the way people train for life

ReBuilding to Last: Strength, Longevity, and the Technology That Multiplies Human Potential

An exclusive interivew with ELLEN TYSON

Written by: Lennard M. Goetze, Ed.D

ELLEN TYSON does not frame fitness as vanity. She frames it as survival, agency, and long-term independence. A strength training coach and Visionbody brand evangelist, Tyson speaks with the authority of lived experience: the arc of her life reshaped by movement after decades of chemical depression, and later refined by a clear-eyed understanding of what aging demands of the body. Her message is simple but uncompromising: muscle is the infrastructure of longevity. “Muscle is your biggest organ of longevity,” Tyson says. “Before supplements, before vitamins—build your muscles.” For Ellen, strength training is not a trend. It is preventive medicine. 

 

FROM SURVIVAL TO STRENGTH: A PERSONAL TURNING POINT

Tyson’s path into strength training was not born of aesthetics or athletic ambition. For much of her adult life, she managed recurring chemical depression. In her forties, she discovered that consistent exercise did something medication never fully achieved: it stabilized her mental health. “Since I was 44… I have not had a depressive episode,” she explains. “I’ve been sad, but not the chemical depression that sent me over the edge every couple of years.”

What began as a social activity became a physiological reset. Over time, she recognized a deeper pattern: movement changed not only her mood, but her metabolism, bone density, and resilience. This realization reframed fitness from self-improvement to self-preservation. “Resistance training is preventative medicine,” she says.

As her children grew older, Tyson transitioned into professional training. The work resonated because it mirrored her own transformation. She no longer trained clients for appearance. “I care not what I look like in a bikini… I care about being strong and healthy. The byproduct is the lean body.”

The outcome is functional longevity: the ability to walk well, recover faster, and remain metabolically active with age.

 

STRENGTH AS THE SPINE OF LONGEVITY

Tyson’s philosophy rests on a clinical truth increasingly supported by research: skeletal muscle is a metabolic organ that influences glucose control, immune competence, hormonal balance, and bone density. As muscle declines with age (sarcopenia), risk rises for falls, insulin resistance, and frailty. Tyson compresses this science into lived wisdom: “Once your muscles go, your immune system goes down, your bone density goes down—everything goes.”

For postmenopausal women, the stakes are higher. Hormonal shifts favor visceral fat gain, accelerate bone loss, and slow recovery. Tyson frames muscle as the first line of defense. “For postmenopausal women… the first line of defense always is muscle.”

Her guidance is not punitive. It is practical: build the engine that supports every other system. She also confronts the most common barrier—time. “If you don’t take time for your wellness, you will be forced to take time for your illness.”

In this framing, exercise is not an added burden; it is a protective investment against the future cost of disease.

 

VISIONBODY: WHEN TECHNOLOGY MULTIPLIES EFFORT

Tyson’s role as a Visionbody brand evangelist grew out of years of experience with electro-muscle stimulation (EMS). Visionbody’s wireless suit delivers
low to mid frequency electrical stimulation to contract muscles deeply during movement, amplifying conventional training. The suit engages most major muscle groups in short sessions, turning 20 minutes into a comprehensive workout.

What differentiates Visionbody in Tyson’s account is depth and comfort. She contrasts higher-frequency stimulation with older EMS systems that sting and work superficially. The Visionbody platform, she explains, reaches deeper muscle layers, increasing oxygen demand and circulation. “It engages, activates your muscles deep and hard—more than you can on your own.”

This physiological load accelerates adaptation while preserving joint safety. For busy professionals and older adults, efficiency matters. “It’s a 20-minute workout. It maximizes your time.” Tyson notes.

In her practice, the suit does not replace training—it sharpens it. She still coaches form, balance, and progressive loading. Technology becomes a multiplier, not a shortcut. The platform’s clinical applications extend beyond fitness. Tyson describes medical protocols for individuals with limited mobility—patients in wheelchairs, neurological conditions, or prolonged bed rest—where stimulation can help maintain circulation and reduce muscle atrophy.

This dual-use design—performance and rehabilitation—reflects her broader belief that wellness tools should scale across health states, not only serve the already fit.

 

STRENGTH AS REHABILITATION, NOT JUST PERFORMANCE

In conversations with clinicians, Tyson emphasizes how muscle preservation intersects with recovery from illness and cancer treatment. She references Visionbody’s origins in survivorship and rebuilding after severe muscle loss. Increased circulation and oxygenation, she notes, support cellular recovery.

While not a medical cure, strength training—augmented by EMS—becomes a rehabilitative bridge back to autonomy. Her coaching style remains cautious with vulnerable populations. Stimulation intensity is titrated; progression is gradual. “Too much of a good thing… you can actually deteriorate muscles if you go too strong.”  The principle mirrors her longevity ethic: sustainable gains beat dramatic but brittle progress.

 

THE EDUCATOR’S ETHIC: TEACHING AGENCY

Tyson’s influence is not confined to training sessions. She identifies as an educator, translating physiology into habits people can sustain. Her most repeated lesson is behavioral: the hardest part is showing up. “The hardest part about working out is actually getting to the gym. Once you’re there, you’re motivated.”

 This framing lowers the psychological barrier to action and builds consistency—the real driver of results. Her messaging to midlife women is resolute and hopeful. “It’s never too late to build muscles.”  She positions strength as a reclaiming of agency during hormonal transitions often framed as decline. In doing so, she reframes longevity as something practiced daily, not postponed to later interventions.

WHY ELLEN TYSON RESONATES

Tyson’s authority is not performative. It emerges from congruence: she practices what she teaches. Her body becomes evidence, but her story carries the proof. She connects mental health, metabolic health, and musculoskeletal resilience into a single narrative of self-stewardship. Technology fits into this arc not as spectacle, but as a pragmatic amplifier of effort. “I don’t understand people who wait until they’re sick to take care of their health,” she says.

In her framework, the body is not a machine to fix when broken; it is an ecosystem to support while it’s working.

THE TAKEAWAY

Ellen Tyson’s message to the longevity movement is blunt and humane: build muscle to protect your future self. Pair disciplined training with smart tools like Visionbody when appropriate. Treat strength as infrastructure—for balance, immunity, bone density, recovery, and mental health. And begin now, not later. Her ethic closes the loop between effort and technology, prevention and performance, body and agency. Strength training, in her view, is not about aesthetics, but actually being powerful from the inside an out. It is about staying capable—long enough to keep living well, longer.

SCIENCE & HEALTH

A Diagnostic Perspective on Movement, Strength, and Restorative Technology

by Robert L. Bard, MD, DABR, FAIUM, FASLMS

Ellen’s story and a review on the Visionbody system through a diagnostic lens reinforces a truth I’ve seen across decades of imaging patients in oncology, metabolic disease, neuroinflammation, and post-treatment recovery: movement and strength are not accessories to wellness—they are foundational biology. When we image the body over time, we see patterns. The patients who retain function, circulation, nerve integrity, and metabolic stability are not simply those who “follow protocols,” but those who preserve muscle engagement, joint mobility, and physiologic loading as part of daily life.

In cancer care and post-treatment surveillance, I repeatedly observe the downstream effects of immobility: sarcopenia, lymphatic stagnation, vascular compromise, neuropathy, and delayed tissue recovery. In diabetes and weight dysregulation, we see microvascular injury, impaired oxygen delivery, and inflammatory burden. In aging populations, we see the quiet erosion of strength precede falls, frailty, and cognitive decline. Imaging does not lie—deconditioning leaves signatures in circulation, tissue quality, and neural signaling. Movement changes the picture.

From a diagnostic standpoint, rehabilitation is not merely physical therapy—it is physiologic restoration. Strength training, when safely prescribed, improves insulin sensitivity, vascular tone, lymphatic flow, and neuromuscular signaling. It supports immune resilience and recovery capacity, particularly in patients navigating chemotherapy, radiation aftercare, endocrine disruption, or chronic inflammatory states. The body repairs itself more efficiently when mechanical loading and movement signal tissues to adapt, rebuild, and revascularize.

Technologies like Visionbody enter this landscape as supportive enablers. As a clinician who integrates non-invasive modalities—such as PEMF and targeted stimulation—I see value in tools that lower barriers to engagement, improve neuromuscular activation, and help patients re-enter movement safely when pain, weakness, or fear of injury limits participation. These technologies are not replacements for movement; they are bridges back to it. When paired with intelligent diagnostics and individualized rehab planning, they can accelerate reconditioning, improve compliance, and restore confidence in patients who have been sidelined by disease or treatment.

Ellen’s work highlights an essential shift: wellness is not passive. From a diagnostic perspective, strength and movement are measurable interventions that change tissue behavior, circulation, and recovery trajectories. The future of rehabilitation—across cancer recovery, metabolic disease, and aging—belongs to integrative models that unite imaging intelligence, non-invasive technologies, and purposeful movement as primary medicine.

 

WHERE ENERGY MEETS EVIDENCE: Imaging the Physiology Of Strength And Recovery This February, Ellen Tyson of Visionbody and Dr. Robert Bard will collaborate on a focused performance review and medical validation initiative examining the clinical impact of Visionbody’s EMS muscle-strengthening technology. The project is designed to move beyond anecdotal claims by applying objective diagnostic imaging and monitoring protocols to evaluate measurable physiological change. Dr. Bard’s interest centers on imaging-guided assessment of EMS-driven energy induction and its real-world effects on neuromuscular activation, muscle strength development, tissue response, and functional regeneration. Of particular interest is how EMS may influence neuromuscular signaling pathways associated with neurotransmitter activity and recovery mechanisms—areas that are increasingly relevant to aging populations, rehabilitation, metabolic dysfunction, and post-treatment recovery. Throughout February, performance data will be documented through serial monitoring and imaging-based observation to identify patterns of response, adaptation, and potential therapeutic relevance. This initiative reflects a growing demand for evidence-based validation of non-invasive technologies entering the clinical and wellness landscape. Findings and clinical observations from this collaboration will be published exclusively in HealthTechReporter.com, offering clinicians, researchers, and informed patients a transparent look at how emerging EMS technologies perform under real diagnostic scrutiny. (Complete feature coming soon)

 

 

Copyright Notice © 2025 Overture Publications. All rights reserved. This work and all materials contained herein are the intellectual property of Overture Publications under the Institute for Global Health Innovations and its authorized contributors. No part of this manuscript may be reproduced, stored in a retrieval system, transmitted in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior written permission from the publisher. All names, images, and materials are protected under applicable copyright and intellectual-property laws in the United States and internationally. Any reference to individuals, institutions, or proprietary entities is for informational purposes only and does not imply endorsement or affiliation unless expressly stated. All trademarks and service marks mentioned are the property of their respective owners.

Modern Neurofeedback

Engineering Brain Self-Regulation Through Precision Diagnostics

By: Lennard M. Goetze, Ed.D / © Copyright 2026- HealthTech Reporter. All rights reserved.

Neurofeedback occupies a rare position in modern neuroscience—part diagnostic instrument, part therapeutic training system. Yet its clinical value depends entirely on how rigorously it is applied, interpreted, and individualized. Mark Smith’s work in neurofeedback distinguishes itself through technical precision, data-driven personalization, and a disciplined clinical framework that treats neurofeedback not as a generalized wellness tool, but as a targeted neuroregulation technology.

Smith’s practice has become a referral destination within trauma-focused and neurological care communities, particularly for individuals with post-traumatic stress, anxiety, depression, traumatic brain injury, autism-related regulation challenges, eating disorders, and post-viral neurological sequelae. Rather than approaching symptoms in isolation, Smith frames each case as a functional brain-network problem—an issue of disrupted communication, abnormal activation patterns, and maladaptive neural rhythms that can be trained toward stability.

Neurofeedback as a Closed-Loop Neuroregulation Technology

At a technical level, neurofeedback is best understood as a closed-loop learning system for the brain. Real-time electroencephalographic (EEG) data is captured from the scalp and processed to quantify patterns of neural activity across multiple frequency bands. These frequency bands—commonly categorized as delta, theta, alpha, beta, and high beta—correspond to different cognitive, emotional, and regulatory states. Smith emphasizes that neurofeedback does not “stimulate” the brain in the traditional sense. Instead, it trains the brain to recognize and shift away from dysregulated patterns. Visual or auditory feedback is provided in real time when neural activity moves toward targeted regulatory ranges. Over repeated sessions, the brain learns to stabilize its own functioning, reinforcing healthier activation and connectivity patterns. This learning process persists beyond the training environment, gradually altering baseline neurophysiological behavior.

This closed-loop framework makes neurofeedback fundamentally different from passive interventions. The patient’s nervous system is not acted upon; it is coached into reorganizing itself. Smith views this as a form of applied neuroplasticity—using the brain’s adaptive capacity to retrain networks that have become entrenched in maladaptive rhythms.

Quantitative Brain Mapping as the Clinical Foundation

A defining element of Smith’s practice is his insistence on objective measurement prior to intervention. Before neurofeedback training begins, patients undergo quantitative EEG (QEEG) brain mapping. This process generates a functional profile of brain activity across multiple cortical regions and frequency bands, creating a data-driven roadmap for treatment design.

During mapping, multiple sensors placed on the scalp capture electrical activity patterns, which are then processed and statistically compared against age-matched normative databases. This comparison reveals areas of under-activation, over-activation, network disconnection, or timing delays in neural communication. Smith uses these quantitative deviations as clinical targets, aligning training protocols with regions and networks most relevant to the patient’s functional complaints.

NEUROFEEDBACK SERVICES OF NY

Importantly, QEEG mapping also allows for longitudinal tracking. Changes in neural patterns can be monitored over time, providing an objective method for evaluating whether neurofeedback is altering underlying brain function rather than merely improving subjective symptoms. Smith views this feedback loop as essential to clinical credibility, particularly when neurofeedback is applied to complex neurological presentations.

 

Trauma and the Neurophysiology of Dysregulation

Trauma occupies a central place in Smith’s clinical focus. From a neurophysiological perspective, trauma represents a persistent disruption of regulatory circuits governing threat detection, emotional modulation, and autonomic stability. Many trauma-affected individuals operate in chronic hyperarousal or dissociative patterns, with neural networks locked into defensive states long after external danger has passed.

Neurofeedback provides Smith with a method to intervene directly at this regulatory level. Instead of relying solely on cognitive or narrative processing of traumatic experiences, neurofeedback targets the underlying neural rhythms associated with survival-mode activation. By training the brain to exit hypervigilant patterns and stabilize network communication, Smith addresses trauma as a functional brain disorder—not simply a psychological narrative. This neurophysiological framing expands trauma care beyond symptom management. It positions neurofeedback as a method for restoring baseline regulatory capacity, potentially improving sleep quality, emotional resilience, attentional stability, and autonomic balance.

Expanding Applications: Migraines, Autism, Pain, and Post-Viral Syndromes

While trauma remains a core area of Smith’s work, his clinical scope extends into migraine disorders, autism spectrum regulation challenges, generalized pain syndromes, and post-viral neurological complications, including long COVID. Each of these conditions reflects distinct patterns of network dysregulation rather than uniform pathology.

Migraines often involve abnormal cortical excitability and sensory processing patterns. Autism-related challenges can reflect atypical connectivity and sensory modulation networks. Chronic pain syndromes may involve altered central processing of nociceptive signals. Post-viral syndromes introduce emerging patterns of neuroinflammation and autonomic instability. Neurofeedback, in Smith’s model, becomes a way to recalibrate these disrupted networks through targeted training rather than symptom suppression alone.

Smith does not present neurofeedback as a universal remedy. Instead, he frames it as a precision intervention suited to specific neuroregulatory patterns identified through quantitative assessment. This restrained clinical positioning is central to his leadership in the field.

Integrating Neurofeedback with Broader Diagnostic Ecosystems

A distinguishing feature of Smith’s methodology is his emphasis on alignment with diagnostic technologies. He views neurofeedback as most powerful when integrated into broader frameworks of neurological assessment—imaging, quantitative analytics, and functional measurement.

By grounding neurofeedback in measurable neurophysiology, Smith helps elevate the technology from alternative modality to legitimate clinical instrument. This diagnostic compatibility enables collaboration with imaging-based disciplines and research-driven clinical environments, where objective validation is a prerequisite for adoption.

Leadership Through Methodological Discipline

Smith’s leadership in neurofeedback is defined not by scale or marketing reach, but by methodological discipline. In a field sometimes diluted by generalized claims, he insists on individualized mapping, targeted protocols, outcome tracking, and ethical clinical boundaries. Neurofeedback, in his framework, is neither a miracle cure nor a passive wellness device—it is a specialized neuroregulation technology that requires technical fluency and clinical restraint.

By positioning neurofeedback as a precision tool for retraining dysfunctional brain networks, Smith contributes to a more credible, research-aligned future for the field. His work reflects an evolving model of brain-based care—one that integrates diagnostics, neuroplastic training, and functional outcome measurement into a coherent clinical discipline.

 

AFTERMATH / PART II

A Diagnostic Perspective on Neurofeedback

By: Dr. Robert L. Bard, MD

My visit to Mark Smith’s office on January 29 was driven by a long-standing curiosity about how emerging non-invasive brain technologies can complement diagnostic imaging and expand the way we understand neurological regulation. As a diagnostic radiologist, my work has always centered on reading pathology through patterns—vascular behavior, tissue response, perfusion dynamics, and structural change. Neurofeedback offered a different lens: not imaging anatomy, but observing function in motion.

What struck me immediately was the emphasis on measurement and individualization. Neurofeedback, as practiced by Mark Smith, is not a generic wellness intervention. It is a data-informed training system that works with real-time brain activity to guide the nervous system toward healthier regulatory patterns. From a diagnostic perspective, this matters. If we expect therapeutic technologies to be credible, they must demonstrate a relationship to measurable physiology. Neurofeedback does exactly that—using objective signals as both guide and outcome reference.

My interest in this field is deeply connected to my work with non-invasive brain scanning and neurological surveillance. Over the years, I have worked with neurologists on ALS, traumatic brain injury, and concussion, where we often see that structural imaging alone does not fully explain functional impairment. Through retinal ultrasound scanning and transcranial Doppler, we are able to observe vascular behavior, microcirculatory dynamics, and perfusion patterns that correlate with cognitive performance, neurological stress, and recovery capacity. Neurofeedback adds a complementary dimension by addressing how neural networks regulate themselves over time.

Another driver of my visit was my ongoing research into neurotoxins and their effects on cognitive decline, neurological stress, and long-term functional deterioration. Environmental and metabolic neurotoxins create subtle yet persistent disturbances in neural regulation long before structural damage becomes visible. Trauma and chronic stress compound this burden by locking the nervous system into survival-mode patterns that accelerate cognitive fatigue and dysregulation. Neurofeedback offers a non-invasive way to intervene earlier in that process—training the brain out of maladaptive loops before degeneration becomes entrenched.

From my perspective, neurofeedback belongs within a broader diagnostic ecosystem. It does not replace imaging; it complements it. Imaging shows us where pathology exists. Functional training shows us how the brain behaves in real time—and how it can be retrained. This visit reinforced my belief that the future of brain care lies in integrated, non-invasive solutions that connect diagnostics, physiology, and functional recovery. Neurofeedback, when practiced with technical discipline, represents a meaningful step in that direction.

© Copyrght 2026- AngioInstitute – Institute for Global Health Innovations. All rights reserved. This work and all materials contained herein are the intellectual property of AngioInstitute (Institute for Global Health Innovations) and its authorized contributors. No part of this manuscript may be reproduced, stored in a retrieval system, transmitted, distributed, or shared in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without prior written permission from the publisher. All content is protected under applicable United States and international copyright, trademark, and intellectual property laws. Any trademarks, service marks, product names, or company names referenced herein are the property of their respective owners and are used for identification purposes only.